TAK Stock Recent News

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BANNOCKBURN, Ill.--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the en.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).

Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.

SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.

SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda has awarded grants to seven nonprofits that share its commitment to creating better health for people and a brighter future for the world.

DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.